<?xml version="1.0" encoding="UTF-8"?>
<ref id="cas14841-bib-0027">
 <label>27</label>
 <mixed-citation publication-type="journal" id="cas14841-cit-0027">
  <string-name>
   <surname>Nakamura</surname>
   <given-names>M</given-names>
  </string-name>, 
  <string-name>
   <surname>Takashima</surname>
   <given-names>A</given-names>
  </string-name>, 
  <string-name>
   <surname>Denda</surname>
   <given-names>T</given-names>
  </string-name>, et al. 
  <article-title>475P Updated analysis and exploratory analysis of primary tumor location in the TRICOLORE trial: A randomized phase III trial of S‐1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first‐line treatment for metastatic colorectal cancer</article-title>. 
  <source xml:lang="en">Ann Oncol</source>. 
  <year>2018</year>;
  <volume>29</volume>(
  <issue>suppl_8</issue>):
  <fpage>23</fpage>.
  <pub-id pub-id-type="pmid">29088323</pub-id>
 </mixed-citation>
</ref>
